CSL Seqirus' cell-based quadrivalent flu vaccine, Flucelvax QUAD, is now available on the National Immunisation Program for the first time to protect at-risk Australians from influenza.
At-risk Australians now have funded access to CSL Seqirus' cell-based flu vaccine
April 3, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
WA Budget includes significant investments in health and medical research
June 20, 2025 - - Latest News -
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 - - Latest News -
Advocate and founder of Rare Cancers Australia steps down as chair
June 20, 2025 - - BioPharma -
Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant
June 19, 2025 - - Latest News -
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 - - Australian Biotech -
NZ Government expands access to melatonin and psilocybin
June 18, 2025 - - Latest News -
Imugene announces US patent allowance for onCARlytics
June 18, 2025 - - Australian Biotech